

PATENT ATTORNEY DOCKET NO. 50004/003004

Certificate of Mailing: Date of	Denosit Februar	ry 3, 2005
Certificate of Marinig. Date of	i Deposit. I eoiuai	1 y J, 2005

I hereby certify under 37 C.F.R. § 1.8(a) that this correspondence is being deposited with the United States Postal Service as first class mail with sufficient postage on the date indicated above and is addressed to Mail Stop AF, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313/1450.

Christine M. Colbert

Printed name of person mailing correspondence

Signature of person mailing correspondence

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

Roy A. Gravel et al.

Art Unit:

1632

Serial No.:

09/487,841

Examiner:

Shin-Lin Chen

Filed:

January 19, 2000

Customer No.:

21559

Title:

HUMAN METHIONINE SYNTHASE REDUCTASE: CLONING, AND METHODS FOR EVALUATING RISK OF NEURAL TUBE

DEFECTS, CARDIOVASCULAR DISEASE, CANCER, AND

DOWN'S SYNDROME

Mail Stop AF Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

STATEMENT UNDER 37 C.F.R. § 1.825

In reply to the Notice to Comply with Requirements for Patent Applications

Containing Nucleotide and/or Amino Acid Sequences that was mailed on January 7, 2005
in connection with the above-captioned application and as required to satisfy the
requirements of 37 C.F.R. §§ 1.821 through 1.825, Applicants enclose an amended
Sequence Listing consisting of 28 sheets to replace the Sequence Listing that was present
in this application prior to this submission.

Applicants' note that SEQ ID NOs: 61 and 62 have been newly added to the sequence listing and prior SEQ ID NO: 61 is now provided as SEQ ID NO: 63. Support for this amendment can be found on page 65, lines 10-13, of the specification.

As required by 37 C.F.R. § 1.821(e), enclosed is a diskette containing a copy of the Sequence Listing in computer readable form, including all previously submitted data with the present amendments incorporated therein.

As required by 37 C.F.R. § 1.821(f), I hereby state that the contents of the computer readable form of the Sequence Listing are the same as the contents of the paper copy.

As required by 37 C.F.R. § 1.821(g), I hereby state that this submission contains no new matter.

If there are any charges or any credits, please apply them to Deposit Account No. 03-2095.

Date: February 3 WOS

Respectfully submitted,

fistina Bieker Brady, Ph.D., P.C.

Reg. No. 39,109

Clark & Elbing LLP 101 Federal Street Boston, MA 02110

Telephone: 617-428-0200 Facsimile: 617-428-7045